Top Smart Score Stocks
Analysts' Top Stocks
Insiders' Hot Stocks
Daily Stock Ratings
Daily Insider Transactions
My Portfolio Analysis
My Public Profile
Find & Follow Experts
Top 25 Wall Street Analysts
Top 25 Financial Bloggers
Top 25 Corporate Insiders
Top 25 Hedge Fund Managers
Top Individual Investors
Ideas & Insights
Calendars & Events
Stock Market Holidays
Plans & Pricing
Biogen’s 4Q Earnings Miss Street Estimates; Shares Fall 5.2%
Biogen’s shares dropped 5.2% on Feb. 3 as the biotech company’s fourth-quarter earnings fell short of analysts’ estimates....
Feb 04, 2021
Biogen Shares Gain 5.5% As FDA Extends Review Period For Alzheimer’s Drug
Biogen shares were up by 5.5% on Jan. 29 after the pharma company announced that the U.S. Food...
Jan 31, 2021
Gilead Sciences or Biogen: Which Biotech Stock is a Better Pick for 2021?
An unprecedented pandemic did not stop the US stock market from finishing 2020 on a high note. The...
Jan 03, 2021
Sage Therapeutics Gets $1.53B From Biogen in a Collaboration Deal
Sage Therapeutics received $1.525 billion from Biogen under the earlier announced collaboration and license agreement to jointly develop...
Jan 03, 2021
Biogen Files For Japan Approval Of Potential Alzheimer Treatment; Street Says Hold
Biogen has filed a new drug application to Japan’s regulator for the approval of aducanumab, its investigational treatment...
Dec 10, 2020
Biogen Bombs at the FDA Panel; J.P. Morgan Weighs In
By a vote of one for, eight against, and two abstaining, the U.S. Food and Drug Administration’s (FDA)...
Nov 07, 2020
Biogen Rockets 44% On “Substantial Evidence” For Alzheimer’s Drug Approval
Shares of Biogen exploded 44% after staff at the US Food and Drug Administration (FDA) concluded in a...
Nov 05, 2020
Biogen’s Tecfidera Now Faces Cipla Generic Launch; Analyst Wary
Global pharma Cipla has announced that it has received final approval for its generic therapeutic equivalent version of...
Sep 29, 2020
AbbVie vs Biogen: Which Drugmaker Scores A ‘Strong Buy’ Street Consensus?
The COVID-19 pandemic has led to a wake-up call for governments, as they realize the significant investment required...
Aug 26, 2020
Biogen Spikes 10% On FDA Fast Review For Potential Alzheimer Treatment
Shares in Biogen leaped 10% on Friday after the company said that the U.S. Food and Drug Administration...
Aug 09, 2020
Biogen Rises 4% As Morgan Stanley Upgrades Stock To Buy
Shares in Biogen (BIIB) rose over 4% in early-market trading on Monday, after Morgan Stanley lifted the stock’s rating...
Jul 27, 2020
Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease
Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase...
Jul 14, 2020
Biogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan
Not all biotechs are highflyers in 2020. Despite some pharma companies’ elevated coronavirus driven valuations, some have had...
Jul 11, 2020
Biogen Files FDA Application For Potential Alzheimer Treatment
Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the...
Jul 09, 2020